Novartis Investigative Site

Natal, Rio Grande do Norte 59075 740

2 studies enrolling now · 11 studies all time

What they study most

ALK Positive Malignancies, ALK-positive Non-small Cell Lung Cancer, Breast Cancer, Heart Failure With Reduced Ejection Fraction, IC-MPGN, Metastatic Breast Cancer, Non-Small Cell Lung Cancer, Paroxysmal Nocturnal Hemoglobinuria (PNH)

Studies at this site

• Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients — Recruiting now
• Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN — Recruiting now
• Roll-over Study to Allow Continued Access to Ribociclib — Running, not enrolling
• Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study — Running, not enrolling
• Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer — Completed
• Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment. — Completed
• Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC) — Completed
• A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. — Completed
• Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor — Completed
• A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges — Completed
• This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure — Stopped early